Shares of Health Care sector company Exelixis moved 0.2% today, and are now trading at a price of $44.75. The Large-Cap stock's daily volume was 1,020,020 compared to its average volume of 2,795,039. The S&P 500 index returned a -0.0% performance.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company is based in Alameda and has 1,147 full time employees. Its market capitalization is $12,332,384,256.
18 analysts are following Exelixis and have set target prices ranging from $29.0 to $48.0 per share. On average, they have given the company a rating of buy. At today's prices, EXEL is trading 11.72% away from its average analyst target price of $40.06 per share.
Over the last year, EXEL's share price has increased by 110.3%, which represents a difference of 99.1% when compared to the S&P 500. The stock's 52 week high is $45.98 per share whereas its 52 week low is $20.14. With average free cash flows of $442.53 Million that have been growing at an average rate of 0.2% over the last 7 years, Exelixis is in a position to continue its strong stock performance trend.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 699,971 | 28,435 | 671,536 | 129.31 |
| 2022 | 333,324 | 40,469 | 292,855 | -12.56 |
| 2021 | 362,614 | 27,706 | 334,908 | 87.48 |
| 2020 | 208,982 | 30,345 | 178,637 | -65.25 |
| 2019 | 526,956 | 12,834 | 514,122 | -22.47 |
| 2017 | 726,849 | 63,700 | 663,149 |
